Research Letter: Exploring the utility of ketamine in child and adolescent mental health: Perspectives of psychiatrists

Abstract

Get full access to this article

View all access options for this article.

References

Dwyer

Stringaris

Brent

, et al. (2020) Annual research review: Defining and treating pediatric treatment-resistant depression. Journal of Child Psychology and Psychiatry, and Allied Disciplines 61: 312–332.

Zhou

Xiao

, et al. (2022) Risk of suicidal behaviors and antidepressant exposure among children and adolescents: A meta-analysis of observational studies. Front Psychiatry 13: 880496.

Malhi

Bell

Bassett

, et al. (2021) The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Australian and New Zealand Journal of Psychiatry 55: 7–117.

Nikolin

Rodgers

Schwaab

, et al. (2023) Ketamine for the treatment of major depression: A systematic review and meta-analysis. EClinicalMedicine 62: 102127.

RANZCP (2022) Use of ketamine in psychiatric practice. Available at: www.ranzcp.org/clinical-guidelines-publications/clinical-guidelines-publications-library/use-of-ketamine-in-psychiatric-practice (accessed 13 June 2023).

Ryan

Hosanagar

(2023) Ketamine use in child and adolescent psychiatry: Emerging data in treatment-resistant depression, insights from adults, and future directions. Current Psychiatry Reports 25: 337–344.

Schwartz

Amminger

Baune

, et al. (2023) The study of ketamine for youth depression (SKY-D): Study protocol for a randomised controlled trial of low-dose ketamine for young people with major depressive disorder. Trials 24: 686.

Zhou

Teng

Zhang

, et al. (2020) Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: A systematic review and network meta-analysis. The Lancet 7: 581–601.